



Enhancing Medication Safety: Insights into Medication Errors Reporting and Handling by the Saudi Food and Drug Authority (SFDA)

Ghadeer M. Banasser, PharmD, FISMP

Senior Alert and Monitoring Expert

Medication Errors Department

Vigilance Executive Directorate, Drug Sector

Saudi Food and Drug Authority

A solid green square is positioned to the left of the 'Outline' heading.

Outline

- Saudi Vigilance Reporting system
- Draft Guidance on Medication Errors Reporting
- Medication Error Reports Handling

Saudi Vigilance

SCAN ME





Report Forms

Report Forms

How to Report

- ✓ Access the Reporting Service
- ✓ Choose a model
- ✓ Filling out the form
- ✓ Sending the Report to specialists

 Drugs & Cosmetics

 National Center for Medical Devices Reporting

 Food Poisoning Report

 Veterinary Products

A solid green square is positioned to the left of the title.

Medication Error Reporting

- Introductory Statement
- Contact Information
- Trade and Generic Name
- Strength
- Dosage Form
- Description of the medication error
- Images?

Medication Error Report



Reporting Purpose

Saudi Food and Drug Authority (SFDA) relies on your reports of Medication Errors related to the naming, labeling, packaging, and design that are associated with drug products, including circumstances such as look-alike container labels or confusing prescribing information that may cause or lead to a medication error, to drive safer practices and prevent patients harm

Contact Information

Email

Mobile

Request Information

Trade Name

Generic Name

Strength

---Select---

Dosage Form

---Select---

Batch Number

Is this report to inform about similarity between medication names, products, inappropriate, or missing and misleading information in packaging and labeling

☐ Yes ☒ No

Medication Error Definition

“A medication error is any **preventable** event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing, order communication, product labeling, packaging, and nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use.”

The National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP)

NCC MERP Index for Categorizing Medication Errors





Contributing Factors?

- # 4 Drug name, label, packaging problem?
(e.g., look-/sound-alike names, look-alike packaging, unclear/absent labeling, faulty drug identification)




Types of Medication Errors

Product-related Medication Errors

Name Similarity
Look-alike / Sound-
alike

Unclear labels
Lack of Critical Information on
products packaging
Strength Expression
Discrepancies (translation/
packaging and labeling)

Design similarity
Unified themes
Look-alike
Packaging



Guidance for Medication Error Reporting

- Draft was released for public comments on July 23, 2023 for two (2) months
- Explains the importance of Med error reporting
- Steps to follow when reporting through the Saudi vigilance reporting system

SCAN ME



Medication Error Reporting Impact



Med Error Report Handling

Product Details (Optional)

Package Size

Package Size

Manufacturer

Distributor/Vendor

Manufacturing Date

Manufacturing Date

End Date

End Date

Has the manufacturer been informed?

☐ Yes ☒ No

Contact Information

Name

Email

Mobile

Profession

Region

Healthcare Provider Name



Save Change



Accept Request

Request More Info

False Report

Transfer Request



Accepted Request

- Feedback to Report Submitter

Request More Info

Request More Info

The Reason

Copy of this message will be sent to the requester with Link for reply

Upload File
(PDF,IMG,WORD,EXCEL)

Choose Files

No file chosen

- You Can Select Multiple Files Press **Ctrl**

Send

Cancel



Interactions with Qualified Person Responsible for Pharmacovigilance (QPPV)

- Med.drug@sFDA.gov.sa
- Event description with images
- Recommendations
 - Product Modification (Trade name & artwork amendments)
 - Dear Health Care Provider Letter (DHCL)
 - Patient Education Materials
- Submit Variation Request

Examples



What's Wrong?



Dear Pharco Pharmaceuticals QPPV,

A medication error report was received through the Saudi Vigilance System (تقيظ) with the concern of strength discrepancy between the outer package labeling (carton label) and inner package labeling of Farcolin (salbutamol sulfate) 0.5% Respirator Solution — attached

While currently used strength expression on outer package is matching the intended concentration of 0.5%, the inner package label does not. Calculating the amount of drug per mL using the information provided on outer package will result in the following concentration (5 mg/mL) which is different from the result of calculating amount per mL strength using inner label data (120 mg (0.121 g)/ 20 mL → 6.05 mg/mL)



However, using any of the currently present strength expressions are discouraged, as they are confusing and require healthcare providers to calculate the dose upon prescribing which is subject to medication error.

Use of a common expression for Salbutamol nebulization solution as 0.5% accompanied by the amount per mL (5 mg/mL) is advised; to follow the innovator (Ventolin®) and since it matches usual prescribed doses of Salbutamol nebulization solution.

Kindly ensure using consistent strength expression across product packaging and labeling (primary and secondary packaging label, SPC, PIL,...etc.) in accordance to aforementioned recommendations, and availability of all critical information on principal display panel of outer packaging label to avoid any medication errors.

Regards,





Salt/Prodrug
(Isavuconazonium sulfate)
Vs. active moiety
(Isavuconazole)



200 mg
1 Vial

Cresemba®
Isavuconazole
(Isavuconazonium sulfate)

كريسيمبا®
إيزافوكونازول
(سلفات الإيزافوكونازونيوم)

٢٠٠ ملغم

hikma.

For Intravenous Use

1 Vial
Powder for Concentrate
for Solution for Infusion

GTIN : 06285101003868
Batch No.:
Mfg. date.:
Exp. date:

Rev: 12/2020 AE



Cresemba® 200 mg
Isavuconazole
(Isavuconazonium sulfate)

200 mg

hikma.

For Intravenous Use

1 Vial
Powder for Concentrate
for Solution for Infusion

GTIN : 06285101003868
Batch No.:
Mfg. date.:
Exp. date:

Prescription-only medicine.
Keep out of reach and sight of children.
Store in a refrigerator (2-8°C).
After reconstitution and dilution with the compatible diluents, it can be stored for 24 hours at 2 to 8°C or 6 hours at room temperature.
Read enclosed leaflet for further information.

بصرف بوصفة طبية.
يحفظ بعيداً عن متناول الأطفال.
يحفظ داخل الثلاجة (2-8°مئوية).
بعد التحضير، مع المحاليل المتوافقة، يمكن تخزينه لمدة 24 ساعة عند درجة حرارة 2 إلى 8°مئوية أو 6 ساعات عند درجة حرارة الغرفة.
اقرأ النشرة المرفقة.

100 mg
14 Hard Capsules

Cresemba®
Isavuconazole
(Isavuconazonium sulfate)

كريسيمبا®
إيزافوكونازول
(سلفات الإيزافوكونازونيوم)

١٠٠ ملغم

hikma.

For Oral Use

14 Hard Capsules

GTIN : 06285101003875
Batch No.:
Mfg. date.:
Exp. date:

Prescription-only medicine.
Keep out of reach and sight of children.
Do not store above 30°C.
Store in the original package in order to protect from moisture.
Read enclosed leaflet for further information.

بصرف بوصفة طبية.
يحفظ بعيداً عن متناول الأطفال.
لا يحفظ عند درجة حرارة أعلى من 30°مئوية.
يحفظ داخل العبوة الأصلية لتحميها من الرطوبة.
اقرأ النشرة المرفقة.

Cresemba® 100 mg
Isavuconazole
(Isavuconazonium sulfate)

100 mg

hikma.

For Oral Use

14 Hard Capsules

GTIN : 06285101003875
Batch No.:
Mfg. date.:
Exp. date:

Prescription-only medicine.
Keep out of reach and sight of children.
Do not store above 30°C.
Store in the original package in order to protect from moisture.
Read enclosed leaflet for further information.

بصرف بوصفة طبية.
يحفظ بعيداً عن متناول الأطفال.
لا يحفظ عند درجة حرارة أعلى من 30°مئوية.
يحفظ داخل العبوة الأصلية لتحميها من الرطوبة.
اقرأ النشرة المرفقة.

Thoughts?



The vial contains Vancomycin hydrochloride equivalent to 500 mg (500,000 IU) Vancomycin. When reconstituted with 10 ml water for injection, each 1 ml contains 50 mg Vancomycin. Must be reconstituted and diluted before use.

Store below 30°C.

To store the reconstituted and diluted solutions:

See enclosed leaflet.

To be dispensed on medical prescription.

For more information: See enclosed leaflet.

Keep out of reach of children.

42024/R10

Colat®

500mg

500mg

Colat®

Vancomycin hydrochloride

IV

Vancomycin hydrochloride

Powder for Solution for Infusion

For Single Use Only

1 vial

tabuk

Tabuk Pharmaceutical Mfg. Co.

2nd Industrial City P.O. Box 4640,

Dammam - Saudi Arabia

التحتن الوريدي

فانكوميسين هيدروكلوريد

مسحوق لحضير محلول الحقن

للاستعمال لمرة واحدة فقط

1 زجاجة

تيبوك

Tabuk Pharmaceutical Mfg. Co.

Dammam - Saudi Arabia

The vial contains: Vancomycin hydrochloride equivalent to 500 mg (500,000 IU) Vancomycin. When reconstituted with 10 ml water for injection, each 1 ml contains 50 mg Vancomycin. Must be reconstituted and diluted before use.

Store below 30°C.

To store the reconstituted and diluted solutions:

See enclosed leaflet.

To be dispensed on medical prescription.

For more information: See enclosed leaflet.

Keep out of reach of children.

42024/R80

Colat®

Vancomycin hydrochloride

500mg

500mg

Colat®

Vancomycin hydrochloride

IV

Powder for Solution for Infusion

For Single Use Only

1 vial

tabuk

Tabuk Pharmaceutical Mfg. Co.

2nd Industrial City, P.O. Box 4640,

Dammam - Saudi Arabia

التحتن الوريدي

فانكوميسين هيدروكلوريد

مسحوق لحضير محلول الحقن

للاستعمال لمرة واحدة فقط

1 زجاجة

تيبوك

Tabuk Pharmaceutical Mfg. Co.

Dammam - Saudi Arabia

B. No:

Mfg:

Exp:

42024/R2

Colat®

500mg

500mg

Colat®

Vancomycin hydrochloride

Powder for Solution for Infusion

For Single Use Only

tabuk

Tabuk Pharmaceutical Mfg. Co.

Dammam - Saudi Arabia

التحتن الوريدي

فانكوميسين هيدروكلوريد

مسحوق لحضير محلول الحقن

للاستعمال لمرة واحدة فقط

1 زجاجة

تيبوك

Tabuk Pharmaceutical Mfg. Co.

Dammam - Saudi Arabia

B. No:

Mfg:

Exp:

4406/R80

Colat®

500mg

500mg

Colat®

Vancomycin hydrochloride

Powder for Solution for Infusion

For Single Use Only

tabuk

Tabuk Pharmaceutical Mfg. Co.

Dammam - Saudi Arabia

التحتن الوريدي

فانكوميسين هيدروكلوريد

مسحوق لحضير محلول الحقن

للاستعمال لمرة واحدة فقط


1 زجاجة

تيبوك

Tabuk Pharmaceutical Mfg. Co.

Dammam - Saudi Arabia

What's Wrong?



Good Day!

We have received report of possible mix-ups between Domine (Dopamine Hydrochloride) 200 mg/ 5 mL (40 mg/mL) concentrate for solution for infusion ampoule with products from different manufacturers which typically occur with small containers — refer to the attached image

As per the SFDA Guidance for Graphic Design of Medication Packaging, the following amendments have to be considered to better differentiate various products and avoid any medication errors:

1. Use paper labeling where possible, and ensure that the label does not wrap completely around the ampoule to allow for inspection of contents. If clear plastic labeling must be used, highlight key information by inverting the text color.
2. Eliminate the overlapping text by keeping the information to minimum, as follow: proprietary name, nonproprietary name, strength, route(s) of administration, warnings or cautionary statements (if any), batch number, expiry date, and MAH.
3. Change the text orientation for the pharmaceutical information presented on the ampoule to be positioned longitudinally (vertically), along the length of the ampoule
4. The quantity per total volume should be the primary and prominent expression, followed in close proximity by quantity per milliliter enclosed by parentheses “i.e., 200 mg/5 mL (40 mg/mL)”.

Kindly acknowledge receipt of this email and submit variation request with the new proposed artworks, ensuring the aforementioned recommendations are applied.



DOMINE® 40 mg/ml
Dopamine hydrochloride 40 mg/ml

5 ml
Concentrate for solution for infusion

Store below 30°C. Protect from light.
After opening the solution is stable for 24 hours below 25° C.
The injection is to be diluted with a suitable parenteral vehicle prior to intravenous infusion.

JPI Manufactured by: Hikma Italia S.P.A. Italy
For: Jazeera Pharmaceutical Industries,
Riyadh - Saudi Arabia
Rev. 11/2015

Batch: . .
Mfg. . .
Exp. . .



For Intravenous Use
Concentrate for
Solution for Infusion
Store below 30°C.
Store in the original
package in order to
protect from light.
Contains sodium
metabisulfite.

Domine®
Each 5 ml contains
200 mg dopamine
hydrochloride.

**200 mg per 5 ml
(40 mg/ml)
(5 ml)**

MAH: Jazeera
Pharmaceutical Industries,
Riyadh - Saudi Arabia
Manufacturer: Hikma Italia
S.P.A., Pavia - Italy

hikma.

Batch no.:
Mfg. date :
Exp. date :

DOMINE® 40 mg/ml
Dopamine hydrochloride

Concentrate for solution for infusion

JPI

5 Ampoules (5 ml)

Rev. 11/2015

GTPN: 062261010002800
Batch no.:
Mfg. date:
Exp. date:

Domine®
Dopamine hydrochloride

دومين®
هيدروكلوريد الدوبامين

**200 mg per 5 ml
(40 mg/ml)**

**٢٠٠ ملغم لكل ٥ ملتر
(٤٠ ملغم/ملتر)**


For Intravenous Use

hikma.

5 Ampoules (5 ml)
Concentrate for Solution for Infusion

للاستخدام الوريدي

٥ زجاجات (٥ ملتر)
محلول للتخفيف للحقن الوريدي



Each ml contains 5000 IU heparin sodium.
Prescription-only medicine.
Do not store above 30°C. Do not freeze.
Store in the original package in order to protect from light.
Read enclosed leaflet for further information.
Contains benzyl alcohol.

MAH: Jazeera Pharmaceutical Industries,
Riyadh - Saudi Arabia
Manufacturer: Hikma Farmaceutica (Portugal),
S.A., Sintra - Portugal

Hikma Heparin®

Solution for Injection/Infusion
For Intravenous and Subcutaneous Use

5000 IU per ml (5 ml)

hikma.

Batch:
Mfg.:
Exp.:

Solution for Injection/Infusion
For Intravenous and Subcutaneous Use
Each 5 ml contains 25,000 IU heparin sodium.
Prescription-only medicine.
Store below 30°C. Avoid freezing.
Store in the original package in order to protect from light.
Read enclosed leaflet for further information.
Contains benzyl alcohol.
MAH: Jazeera Pharmaceutical Industries,
Riyadh - Saudi Arabia
Manufacturer: Hikma Farmaceutica (Portugal),
S.A., Sintra - Portugal

Hikma Heparin®

Heparin sodium

25,000 IU per 5 ml (5,000 IU/ml) (5 ml)

hikma.

UNVARISHED AREA
Batch:
Mfg.:
Exp.:



Previous Aluminum artwork

Adrenaline 0.1 mg/mL 1 mg - 10 ml

Adrenaline 0.1 mg/mL 1 mg - 10 ml

Adrenaline 0.1 mg/mL

Sulphite free
Solution for injection in pre-filled syringe
Intravenous, intraosseous or endotracheal use

1 mg - 10 ml

Do not store above 25°C
After opening the pouch, the product must be used immediately
This pouch includes an oxygen absorbing sachet which contains iron that may interact with magnetic fields.

ADUR-141

Ref: 130400

Aluminum artwork updated (with highlights)

Adrenaline **1 mg - 10 ml** (0.1 mg/mL)

Adrenaline **1 mg - 10 ml** (0.1 mg/mL)

Adrenaline

Sulphite free
Solution for injection in pre-filled syringe
Intravenous, intraosseous or endotracheal use

1 mg - 10 ml
(0.1 mg/mL)

Do not store above 25°C
After opening the pouch, the product must be used immediately
This pouch includes an oxygen absorbing sachet which contains iron that may interact with magnetic fields.

ADUR-141

Ref: 130400





The way Forward!

- Awareness about Medication Error Reporting
- Optional → Mandatory requirements!
- National Collaborations (CBAHI, SPSC)
- International Collaborations (IMSN)





Contact Us

Med.drug@sfda.gov.sa



Kingdom of Saudi Arabia
Saudi Food & Drug Authority

「
Thank You